Navigation Links
Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
Date:4/2/2009

CHARLOTTESVILLE, Virginia, April 2 /PRNewswire/ -- Biovista Inc. today announced that BVA-101, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-101, an existing drug that Biovista repositioned in MS and is aimed at neuroprotection, was shown to have both efficacy in reducing symptoms and no toxic effects in this well established model of MS.

"We are excited about these early results that confirm the predictive capability of our repositioning platform technology and encourage us to further develop this compound in a disease area where there is a significant need for new therapies" said Aris Persidis, Ph.D., President of Biovista. "What is also encouraging is that we reached this stage just 4 months after deciding to work in MS. At the present time we are exploring all options available to us, including the further co-development with a pharmaceutical company and the licensing of the IP to a generics company" Dr. Persidis added.

About Biovista's BVA-101 trial in the MS EAE-MOG model

MS is a chronic inflammatory disease of the CNS with unknown etiology. It is the most frequent non-traumatic disabling neurologic disease among young adults, with 12,000 new diagnoses per year in the US alone, and over 2.5 million patients worldwide. In the animal proof of concept trial, BVA-101 was compared to dexamethasone, a potent anti-inflammatory and immunosuppressive drug that is efficient in accelerating the recovery from MS relapses but too toxic for chronic use. BVA-101 induced a statistically significant reduction of EAE severity, the magnitude of which was statistically similar to that caused by dexamethasone.

About Biovista's repositioning pipeline and technology platform

Biovista applies high-throughput discovery efforts to finding solutions for commerci
'/>"/>

SOURCE Biovista Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... NJ (PRWEB) May 21, 2015 Patent ... a method for diagnostic or therapeutic imaging within a ... apparatus uses an endoscope having a low cost, single-use ... USPTO filing date was October 18, 2013 and the ... The technology enables the physician to customize the lighting ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
(Date:5/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ) ... in HW_Technical Insights" report to their offering. ... trends in the Health and Wellness sector and has ... an impact in the year 2015. The research service ... health and wellness technologies that are anticipated to have ...
(Date:5/20/2015)... global genotyping market is expected to grow at a ... to 2020 to reach $17.0billion in 2020. Genotyping tests ... process and to provide personalized therapy, factors that are ... key manufacturers to offer advanced and innovative products for ... market data tables & 37 figures spread through 200 ...
Breaking Biology Technology:IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Top Technologies in the Health and Wellness Industry 2015 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5
... DARA BioSciences(TM),(Nasdaq: DARA ) announced today the appointment ... Mr. Cochrane was appointed to fill a Board,vacancy and ... appointment was effective February 21, 2008., In making ... are pleased that Haywood has joined us as a ...
... PITTSBURGH, Feb. 27 Mylan Inc. (NYSE: ... Holdings, Ltd., a wholly,owned subsidiary of Forest Laboratories, ... 2006 agreement to commercialize, develop and distribute the,novel ... in,the United States for the treatment of hypertension. ...
... ZARS Pharma, Inc. announced,today that Rapydan(R) (70 ... received marketing authorization in Sweden, the United ... Republic, Greece, Ireland,Norway and Portugal following the ... Pharma has licensed the European sales and,marketing ...
Cached Biology Technology:DARA BioSciences, Inc. Announces Appointment of New Director to Board 2Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement 2Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement 3ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe 2ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe 3
(Date:5/11/2015)... SAN JOSE, Calif. , May 11, 2015 ... leading developer of human interface solutions, today announced ... Senior Vice President and Chief Financial Officer, reporting ... Mr. Ali replaces Synaptics, current Chief Financial Officer, ... in December 2014. Mr. Ali ...
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
(Date:5/8/2015)... , May 8, 2015 Synaptics Inc. (NASDAQ: ... announced that members of the executive management team will present ... Annual Technology, Media and Telecom Conference Date: May 18, ... Boston, MA Cowen and ... Time: 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... University has completed the first comprehensive map of the ... of higher organisms operate, according to a report this ... is a breakthrough in understanding mechanisms of how proteins ... master regulator molecules called protein kinases. Although protein kinases ...
... volcanic rock in Mexico are either extremely old - more ... presence in the Western Hemisphere - or not footprints at ... Nature. , The study was conducted by geologists at the ... part of an investigative team of geologists and anthropologists from ...
... strand of molecules plays a role in how our arms ... light on perplexing bits of material once dismissed as genetic ... University. , The research, available today in the online edition ... called microRNAs act as protective mechanisms in healthy development not ...
Cached Biology News:Yale scientists decipher 'wiring pattern' of cell signaling networks 2Alleged 40,000-year-old human footprints in Mexico much, much older than thought 2Alleged 40,000-year-old human footprints in Mexico much, much older than thought 3Alleged 40,000-year-old human footprints in Mexico much, much older than thought 4MicroRNA may have fail-safe role in limb development 2